Teva Pharmaceuticals Industries Ltd., commonly known as Teva, is a global leader in the pharmaceutical industry, headquartered in Israel (IL). Founded in 1901, Teva has established a strong presence in over 60 countries, focusing on the development, production, and marketing of generic and specialty medicines. With a diverse portfolio that includes a wide range of therapeutic areas such as central nervous system disorders, oncology, and respiratory conditions, Teva is renowned for its commitment to accessibility and innovation. The company’s core products, including the widely used Copaxone and a robust selection of generic medications, set it apart in a competitive market. Teva's notable achievements include being one of the largest generic drug manufacturers globally, reflecting its significant market position and dedication to improving patient outcomes through affordable healthcare solutions.
How does Teva Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Teva Pharmaceuticals's score of 85 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Teva Pharmaceuticals reported total greenhouse gas (GHG) emissions of approximately 4,406,116,000 kg CO2e, with emissions distributed across various scopes: 243,603,000 kg CO2e for Scope 1, 218,504,000 kg CO2e for Scope 2 (market-based), and a significant 4,066,116,000 kg CO2e for Scope 3. This represents a slight decrease in Scope 3 emissions from 2023, where total emissions were about 4,320,235,000 kg CO2e. Teva has set ambitious targets to reduce its carbon footprint. The company aims to achieve a 25% reduction in absolute Scope 1 and 2 GHG emissions by 2025 and a 46% reduction by 2030, using 2019 as the baseline year. Additionally, Teva has committed to reducing its absolute Scope 3 emissions by 25% by 2030, with a 2020 baseline. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Teva has also announced its intention to achieve net-zero emissions across its operations and value chain by 2045. This long-term commitment reflects the company's recognition of the urgent need for climate action and its role in the pharmaceutical industry. Overall, Teva Pharmaceuticals is actively working towards significant emissions reductions while maintaining transparency in its reporting and commitments.
Access structured emissions data, company-specific emission factors, and source documents
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Teva Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.